Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (24)	4/28/2002 8:38:17 PM
From: mopgcw	Read Replies (1) \| Respond to of 276

Illumina Signs Genotyping Services Agreement With University of California, San Diego and San Diego VA Healthcare System BeadArray(TM) Technology To Help Correlate SNP Genotypes with Bipolar Psychiatric Disorders SAN DIEGO--(BW HealthWire)--April 25, 2002-- Illumina, Inc. announced today that it has signed a commercial agreement with the University of California, San Diego (UCSD), to provide single nucleotide polymorphism (SNP) genotyping services on a sample collection provided by the University's Laboratory of Psychiatric Genomics. Under the terms of the agreement, Illumina will use its BeadArray technology to genotype specified SNPs in the sample set. Illumina will also identify potential SNPs for the study and design functional assays for the SNP loci, many of which are located on chromosome 22 and believed to be associated with bipolar disorders and schizophrenia. The study will be funded by a grant from the Department of Veterans Affairs. Further details about the agreement were not disclosed. Jay Flatley, Illumina President & CEO, noted ``UCSD is increasingly at the forefront of groundbreaking research in the field of psychiatry. We're very pleased to work with UCSD on this study, the results of which may provide a better understanding of the genetic basis of bipolar psychiatric disorders and suggest a clearer path for therapeutic development and improved patient outcomes. We're also excited to see further deployment of BeadArray technology in our services operation.'' Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.